HCW Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . HCW Biologics
HCWB Stock  USD 0.36  0.02  5.26%   
HCW Biologics financial statements provide useful quarterly and yearly information to potential HCW Biologics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on HCW Biologics financial statements helps investors assess HCW Biologics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting HCW Biologics' valuation are summarized below:
Gross Profit
4.1 M
Market Capitalization
11.9 M
Enterprise Value Revenue
7.9506
Revenue
3.9 M
Earnings Share
(1.05)
We have found one hundred twenty available fundamental trends for HCW Biologics, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to confirm all of HCW Biologics regular market performance against the performance between 2010 and 2025 to make sure the company can sustain itself next year. The current year's Market Cap is expected to grow to about 71.8 M. The current year's Enterprise Value is expected to grow to about 62.6 M

HCW Biologics Total Revenue

3.91 Million

Check HCW Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HCW Biologics' main balance sheet or income statement drivers, such as Interest Income of 610.2 K, Depreciation And Amortization of 717.9 K or Interest Expense of 201.3 K, as well as many indicators such as Price To Sales Ratio of 30.12, Dividend Yield of 0.0272 or PTB Ratio of 3.59. HCW financial statements analysis is a perfect complement when working with HCW Biologics Valuation or Volatility modules.
  
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

HCW Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets33.9 M32.8 M19.5 M
Slightly volatile
Other Current Liabilities1.6 M3 M1.1 M
Slightly volatile
Total Current Liabilities10.6 M10.1 M2.9 M
Slightly volatile
Total Stockholder Equity27.6 M15.5 M15.6 M
Slightly volatile
Property Plant And Equipment Net24.7 M23.5 M6.4 M
Slightly volatile
Accounts Payable7.4 M7.1 M1.6 M
Slightly volatile
Cash3.9 M4.1 M8 M
Very volatile
Non Current Assets Total26.7 M25.4 M7.7 M
Slightly volatile
Non Currrent Assets Other61.8 K65 K80.4 K
Slightly volatile
Other Assets218.8 K384 K127.5 K
Slightly volatile
Cash And Short Term Investments3.9 M4.1 M10.2 M
Pretty Stable
Common Stock Total Equity4.3 K4.1 K1.5 K
Slightly volatile
Common Stock Shares Outstanding28.9 M32.3 M35.8 M
Slightly volatile
Liabilities And Stockholders Equity33.9 M32.8 M19.5 M
Slightly volatile
Non Current Liabilities Total7.6 M7.2 M2 M
Slightly volatile
Other Current Assets1.3 M1.5 M661.3 K
Slightly volatile
Other Stockholder Equity54.7 M96.6 M25 M
Slightly volatile
Total Liabilities18.2 M17.3 M4.6 M
Slightly volatile
Property Plant And Equipment Gross28.4 M27 M7.1 M
Slightly volatile
Total Current Assets7 M7.4 M11.7 M
Slightly volatile
Capital Stock3.1 K3.2 K13.6 M
Slightly volatile
Common Stock2.6 K4.1 K1.4 K
Slightly volatile
Property Plant Equipment13 M12.4 M4.4 M
Slightly volatile
Short and Long Term Debt Total4.9 M7.2 M2.3 M
Slightly volatile
Net Receivables917.3 K1.4 M2 M
Slightly volatile
Inventory1.5 M1.6 M876.6 K
Slightly volatile
Short Term Debt31.1 K32.8 K908.9 K
Pretty Stable
Long Term Debt5.1 M5.7 M6.3 M
Slightly volatile
Capital Surpluse66.4 M74.7 M81.4 M
Slightly volatile
Non Current Liabilities Other11.4 K12.8 K14 K
Slightly volatile

HCW Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income610.2 K581.2 K215.8 K
Slightly volatile
Depreciation And Amortization717.9 K1.3 M567.7 K
Slightly volatile
Selling General Administrative15.8 M15 M4.9 M
Slightly volatile
Other Operating Expenses17.8 M32.8 M12.4 M
Slightly volatile
Research Development8.3 M8.8 M6.5 M
Slightly volatile
Cost Of Revenue2 M2.6 M1 M
Slightly volatile
Total Operating Expenses16.4 M30.2 M11.7 M
Slightly volatile
Reconciled Depreciation748.2 K1.3 M577.2 K
Slightly volatile
Total Other Income Expense Net872.9 K831.3 K241 K
Slightly volatile
Selling And Marketing Expenses3.7 M4.2 M4.6 M
Slightly volatile

HCW Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Borrowings3.9 M7.4 M2.3 M
Slightly volatile
Stock Based Compensation1.2 M1.2 M305.7 K
Slightly volatile
Begin Period Cash Flow27 M25.7 M7.7 M
Slightly volatile
Depreciation751.2 K1.3 M579.2 K
Slightly volatile
Other Non Cash Items6 M5.7 M1.4 M
Slightly volatile
Capital Expenditures4 M7.1 M2.7 M
Slightly volatile
Issuance Of Capital Stock13.3 K14 K12.6 M
Pretty Stable
End Period Cash Flow3.9 M4.1 M8 M
Very volatile
Dividends Paid2.3 M2.5 M2.8 M
Slightly volatile
Cash And Cash Equivalents Changes8.5 M9.5 M10.4 M
Slightly volatile
Cash Flows Other Operating1.9 M2.1 M2.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio30.1217.8844.0203
Slightly volatile
Dividend Yield0.02720.03060.0334
Slightly volatile
PTB Ratio3.593.7817.9421
Slightly volatile
Days Sales Outstanding162227193
Slightly volatile
Book Value Per Share0.560.340.4122
Slightly volatile
Average Payables3.5 M3.3 M1 M
Slightly volatile
Stock Based Compensation To Revenue0.330.320.0872
Slightly volatile
Capex To Depreciation3.784.923.9685
Pretty Stable
PB Ratio3.593.7817.9421
Slightly volatile
EV To Sales28.918.9842.4536
Slightly volatile
Inventory Turnover2.82.670.8981
Slightly volatile
Days Of Inventory On Hand1341421.1 K
Slightly volatile
Payables Turnover0.40.431.2616
Very volatile
Sales General And Administrative To Revenue4.354.141.3817
Slightly volatile
Average Inventory1.1 M802.1 K1.2 M
Slightly volatile
Research And Ddevelopement To Revenue1.562.431.8085
Pretty Stable
Capex To Revenue1.01.960.5438
Slightly volatile
Cash Per Share0.08560.09010.277
Pretty Stable
Days Payables Outstanding932888413
Slightly volatile
Income Quality1.141.040.9816
Pretty Stable
Current Ratio0.80.847.4242
Pretty Stable
Tangible Book Value Per Share0.560.340.4122
Slightly volatile
Receivables Turnover1.581.673.4579
Slightly volatile
Graham Number1.782.181.5265
Slightly volatile
Shareholders Equity Per Share0.560.340.4122
Slightly volatile
Debt To Equity0.440.420.1315
Slightly volatile
Capex Per Share0.080.160.069
Slightly volatile
Average Receivables220.3 K247.8 K270.2 K
Slightly volatile
Revenue Per Share0.140.0910.1196
Pretty Stable
Interest Debt Per Share0.10.170.0618
Slightly volatile
Debt To Assets0.10.20.075
Slightly volatile
Operating Cycle216227294
Pretty Stable
Price Book Value Ratio3.593.7817.9421
Slightly volatile
Days Of Payables Outstanding932888413
Slightly volatile
Ebt Per Ebit1.081.121.0013
Slightly volatile
Effective Tax Rate0.0130.01080.0119
Pretty Stable
Company Equity Multiplier1.061.911.2274
Slightly volatile
Long Term Debt To Capitalization0.180.290.1681
Slightly volatile
Total Debt To Capitalization0.30.290.1012
Slightly volatile
Debt Equity Ratio0.440.420.1315
Slightly volatile
Quick Ratio0.80.847.302
Pretty Stable
Net Income Per E B T1.081.141.0034
Slightly volatile
Cash Ratio0.450.475.7111
Slightly volatile
Days Of Inventory Outstanding1341421.1 K
Slightly volatile
Days Of Sales Outstanding162227193
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.041.151.2272
Very volatile
Price To Book Ratio3.593.7817.9421
Slightly volatile
Fixed Asset Turnover0.150.161.8506
Slightly volatile
Debt Ratio0.10.20.075
Slightly volatile
Price Sales Ratio30.1217.8844.0203
Slightly volatile
Asset Turnover0.190.110.226
Slightly volatile
Gross Profit Margin0.320.230.3593
Slightly volatile
Price Fair Value3.593.7817.9421
Slightly volatile

HCW Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap71.8 M50.8 M76.9 M
Slightly volatile
Enterprise Value62.6 M53.9 M66.9 M
Slightly volatile

HCW Fundamental Market Drivers

Cash And Short Term Investments3.6 M

HCW Upcoming Events

26th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About HCW Biologics Financial Statements

HCW Biologics stakeholders use historical fundamental indicators, such as HCW Biologics' revenue or net income, to determine how well the company is positioned to perform in the future. Although HCW Biologics investors may analyze each financial statement separately, they are all interrelated. For example, changes in HCW Biologics' assets and liabilities are reflected in the revenues and expenses on HCW Biologics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in HCW Biologics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue2.1 M2.2 M
Total Revenue3.3 M3.9 M
Cost Of Revenue2.6 M2 M
Stock Based Compensation To Revenue 0.32  0.33 
Sales General And Administrative To Revenue 4.14  4.35 
Research And Ddevelopement To Revenue 2.43  1.56 
Capex To Revenue 1.96  1.00 
Revenue Per Share 0.09  0.14 
Ebit Per Revenue(10.41)(9.89)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
CRMSalesforce
CCitigroup
GMGeneral Motors
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
How To Invest In HCW
Details
Is HCW Stock a good investment?
Details
What is HCW Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of HCW Biologics Correlation against competitors.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Revenue Per Share
0.107
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.70)
Return On Equity
(3.44)
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY